Immediate Impact

1 from Science/Nature 64 standout
Sub-graph 1 of 22

Citing Papers

Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity
2024 Standout
Chemically Modified Platforms for Better RNA Therapeutics
2024 Standout
2 intermediate papers

Works of Yoonjin Cho being referenced

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
2014
Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-Naïve Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
2014

Author Peers

Author Last Decade Papers Cites
Yoonjin Cho 377 324 5 150 14 473
Nilima Parry‐Jones 308 309 17 92 19 485
Mads Hansen 254 307 1 136 10 491
Iwona Wlodarska 227 245 5 91 14 427
Evgenii A. Osmanov 202 347 4 110 22 484
Yuh Shan Lee 372 344 64 17 510
Lucia Morello 313 307 9 82 15 429
Kamlai Saiya-Cork 196 218 8 187 15 473
Елена Бибикова 318 234 15 182 15 515
Gianluca Schiavoni 269 170 14 182 17 431
Arnau Montraveta 234 180 2 279 17 486

All Works

Loading papers...

Rankless by CCL
2026